Sélectionner la langue
GDF-15
GDF-15 Informations sur la molécule
| Nom anglais | Growth/differentiation factor 15 | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 10 | Alias de la cible | Placental TGF-beta，GDF-15，MIC1，PTGFB，MIC-1，PLAB，NSAID-activated gene 1 protein，Growth Differentiation Factor 15，Non-Steroidal Anti-Inflammatory Drug-Activated Gene-1，Placental Bone Morphogenetic Protein，NRG-1，PDF，Growth/Differentiation Factor 15，Macrophage Inhibitory Cytokine-1，PTGF-Beta，NSAID-regulated gene 1 protein，GDF15，Prostate Differentiation Factor，Macrophage Inhibitory Cytokine 1，NAG-1，NSAID (Nonsteroidal Anti-Inflammatory Drug)-Activated Protein 1 |
| Phase de R&D la plus avancée | Phase 3 Clinical | ||
| Nom anglais | Growth/differentiation factor 15 |
| Alias de la cible | Placental TGF-beta，GDF-15，MIC1，PTGFB，MIC-1，PLAB，NSAID-activated gene 1 protein，Growth Differentiation Factor 15，Non-Steroidal Anti-Inflammatory Drug-Activated Gene-1，Placental Bone Morphogenetic Protein，NRG-1，PDF，Growth/Differentiation Factor 15，Macrophage Inhibitory Cytokine-1，PTGF-Beta，NSAID-regulated gene 1 protein，GDF15，Prostate Differentiation Factor，Macrophage Inhibitory Cytokine 1，NAG-1，NSAID (Nonsteroidal Anti-Inflammatory Drug)-Activated Protein 1 |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 10 |
| Phase de R&D la plus avancée | Phase 3 Clinical |
GDF-15 Liste de produits
- Attribut
Protein (6)Kits (1)
- Bibliothèque de produits
En ligne (7)
- Espèces
Human (5)Cynomolgus (1)Mouse (1)
- Étiquette
His Tag (3)Fc Tag (1)Avi Tag & Fc Tag (1)His Tag & Avi Tag (1)- (1)
- Marqueur
Unconjugated (4)Biotin-labeled (2)- (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HOT GD5-H5149 |  Human | E. coli | Human GDF-15 / MIC-1 Protein, His Tag, low Endotoxin |  |  |  |  Ajouter au panier |
HOT GD5-H5269 | Human | HEK293 | Human GDF-15 / MIC-1 Protein, Fc Tag (MALS verified) |  | | | Ajouter au panier |
HOT GD5-H81Q3 | Human | E. coli | Biotinylated Human GDF-15 / MIC-1 Protein, His,Avitag™ |  | | | Ajouter au panier |
HOT GD5-C5148 |  Cynomolgus | E. coli | Cynomolgus GDF-15 / MIC-1 Protein, His Tag, low endotoxin |  | | | Ajouter au panier |
CEA-C077 | Human | - | Human GDF-15 ELISA Kit | Ajouter au panier | |||
GD5-H82F9 | Human | HEK293 | Biotinylated Human GDF-15 / MIC-1 Protein, Avitag™, Fc Tag (MALS verified) |  | | | Ajouter au panier |
GD5-M5149 |  Mouse | E. coli | Mouse GDF-15 / MIC-1 Protein, His Tag |  | | | Ajouter au panier |
Quantité totale7
- 1
GDF-15Contexte de la molécule
Growth Differentiation Factor 15 (GDF-15), also called Macrophage Inhibitory Cytokine 1 (MIC-1). Expression of MIC-1 mRNA in monocytoid cells is up-regulated by a variety of stimuli associated with activation, including interleukin 1β, tumor necrosis factor α (TNF-α), interleukin 2, and macrophage colony-stimulating factor but not interferon γ, or lipopolysaccharide (LPS). It is highly expressed in cardiomyocytes, adipocytes, macrophages, endothelial cells, and vascular smooth muscle cells in normal and pathological condition. GDF-15 increases during tissue injury and inflammatory states and is associated with cardiometabolic risk. Increased GDF-15 levels are associated with cardiovascular diseases such as hypertrophy, heart failure, atherosclerosis, endothelial dysfunction, obesity, insulin resistance, diabetes, and chronic kidney diseases in diabetes. Increased GDF-15 level is linked with the progression and prognosis of the disease condition.
GDF-15Alias de la molécule
GDF15,GDF-15,MIC-1,MIC1,NAG-1,PDF,PLAB,PTGFB,NRG-1
Plateforme de commerce de projets d'anticorps
| Nom du projet | Phase du projet | Type de molécule | Source de molécule | Domain thérapeutique | Indication |
|---|---|---|---|---|---|
| GDF15 mAb - 01 | PCC | Monoclonal | Humanized Mouse | Metabolism | Solid tumor,Cancer cachexia |
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Visugromab | CTL-002 | Phase 3 Clinical | CatalYm GmbH | Cachexia; Carcinoma, Non-Small-Cell Lung; Solid tumours; Urinary Bladder Neoplasms | Details |
| Ponsegromab | PF-06946860 | Phase 3 Clinical | Pfizer Inc | Anorexia; Breast Neoplasms; Cachexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Fatigue; Feeding and Eating Disorders; Heart Failure; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms | Details |
| NGM-120 | NGM-120 | Phase 2 Clinical | NGM Biopharmaceuticals Inc | Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Hyperemesis Gravidarum; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| GDF15 agonist (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus | Details | |
| NN-9215 | Human-GDF15; MIC-1; NN-9215; LA-GDF15 | Phase 1 Clinical | Novo Nordisk A/S | Obesity | Details |
| GFS-202-A | GFS-202-A; GFS202A | Phase 1 Clinical | Genfleet Therapeutics (Shanghai) Co Ltd | Cachexia | Details |
| GB-18 | GB-18; GB18 | Phase 1 Clinical | Shandong Kexing Bio-Products Co Ltd | Cachexia | Details |
| CIN-109 | CIN-109; JNJ-9090 | Phase 1 Clinical | Janssen Sciences Ireland Unlimited Company | Obesity | Details |
| MBL-949 | MBL-949 | Phase 1 Clinical | Novartis Pharma Ag | Diabetes Mellitus; Obesity | Details |
| AV-380 | AV-380 | Phase 1 Clinical | Aveo Pharmaceuticals Inc | Cachexia | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques
Partager vers :